Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

Cyclacel Pharmaceuticals, Inc. Form 4 February 21, 2008

FORM 4					OMB AP	PROVAL
		D STATES	SECURITIES AND EXCHANGE C Washington, D.C. 20549	COMMISSION	OMB Number:	3235-0287
Check this box if no longer	Expires:	January 31, 2005				
subject to Section 16. Form 4 or		EMENT OI	Estimated av	•		
Form 4 orresponse(f)Form 5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,obligationsSection 17(a) of the Public Utility Holding Company Act of 1935 or Sectionsee Instruction30(h) of the Investment Company Act of 19401(b).1000000000000000000000000000000000000						
(Print or Type Respon	nses)					
1. Name and Address HENNEY CHRI	•	e –	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of I Issuer	Reporting Perso	on(s) to
			Cyclacel Pharmaceuticals, Inc. [CYCC]	(Check	all applicable)	
(Last) ((First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	X Director Officer (give ti	itle Other	Owner (specify
200 CONNELL DRIVE, SUITE02/19/20081500					below)	
Ģ	Street)		4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joi Applicable Line)	nt/Group Filing	g(Check
BERKELEY HE	IGHTS, N	NJ 07922		_X_Form filed by On Form filed by Mo Person	1 0	

(City)	(State)	(Zip) Tak	ole I - Non-	Derivative	Secu	rities A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8) Code V	4. Securit onAcquired Disposed (Instr. 3, 4 Amount	(A) o of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount o
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: Cyclacel Pharmaceuticals, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)		r)	(Instr. 3 and 4	4)
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Share
Option	\$ 4.31	02/19/2008		А	50,000	02/19/2008(1)	02/19/2018	Common Stock	50,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
HENNEY CHRISTOPHER S 200 CONNELL DRIVE, SUITE 1500 BERKELEY HEIGHTS, NJ 07922	Х					
Signatures						
101 Christopher S						

/s/ Christopher S Henney	02/20/2008
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options will vest ratably over a 48-month period.

(2) The options were granted to Mr. Henney for his services as a vice chairman of the board of directors of Cyclacel Pharmaceuticals, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.